Results 121 to 130 of about 6,478 (160)

Nirmatrelvir+ritonavir

Reactions Weekly, 2023
  +7 more sources

Nirmatrelvir+ritonavir/tacrolimus

Reactions Weekly, 2023
  +9 more sources

Nirmatrelvir+ritonavir

Reactions Weekly, 2022
openaire   +2 more sources

Nirmatrelvir+ritonavir/tacrolimus

Reactions Weekly, 2022
  +4 more sources

Nirmatrelvir+ritonavir

Reactions Weekly
  +5 more sources

Nirmatrelvir/ritonavir in COVID-19 patients with haematological malignancies: a report from the EPICOVIDEHA registry

EClinicalMedicine, 2023
Iker Falces-Romero, Francesco Marchesi, Livio Pagano   +2 more
exaly  

Dobutamine/nirmatrelvir+ritonavir

Reactions Weekly, 2023
openaire   +1 more source

Nirmatrelvir-Ritonavir (Paxlovid)

Canadian Journal of Health Technologies
CADTH reimbursement reviews are comprehensive assessments of the clinical effectiveness and cost-effectiveness, as well as patient and clinician perspectives, of a drug or drug class. The assessments inform non-binding recommendations that help guide the reimbursement decisions of Canada's federal, provincial, and territorial governments, with the ...
openaire   +1 more source

Paxlovid (Nirmatrelvir/Ritonavir): A new approach to Covid-19 therapy?

Biomedicine and Pharmacotherapy, 2023
Zatollah Asemi, Michael R. Hamblin, Hossein Bannazadeh Baghi   +2 more
exaly  

Molnupiravir/nirmatrelvir+ritonavir

Reactions Weekly, 2023
  +4 more sources